Christopher Tomlinson

Dr. Christopher Tomlinson

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2022 in Circulation
Verified
Journal Article
Open access
PDF file
RKRochelle Knight
Rochelle Knight
VWVenexia Walker
Venexia Walker
SISamantha Ip
Samantha Ip
JCJennifer A. Cooper
Jennifer A. Cooper
TBThomas Bolton
Thomas Bolton
FSfor the CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study
for the CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study
Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a prothrombotic state, but long-term effects of COVID-19 on incidence of vascular diseases are unclear. Methods: We studied vascular diseases after COVID-19 diagnosis in population-wide anonymized linked English and Welsh electronic health records from January 1 to December 7, 2020. We estimated adjusted hazard ratios comparing the incidence of arterial thromboses and venous thromboembolic events (VTEs) after diagnosis of COVID-19 with the incidence in people without a COVID-19 diagnosis. We conducted subgroup analyses by COVID-19 severity, demographic characteristics, and previous history. Results: Among 48 million adults, 125 985 were hospitalized and 1 319 789 were not hospitalized within 28 days of COVID-19 diagnosis. In England, there were 260 279 first arterial thromboses and 59 421 first VTEs during 41.6 million person-years of follow-up. Adjusted hazard ratios for first arterial thrombosis after COVID-19 diagnosis compared with no COVID-19 diagnosis declined from 21.7 (95% CI, 21.0–22.4) in week 1 after COVID-19 diagnosis to 1.34 (95% CI, 1.21–1.48) during weeks 27 to 49. Adjusted hazard ratios for first VTE after COVID-19 diagnosis declined from 33.2 (95% CI, 31.3–35.2) in week 1 to 1.80 (95% CI, 1.50–2.17) during weeks 27 to 49. Adjusted hazard ratios were higher, for longer after diagnosis, after hospitalized versus nonhospitalized COVID-19, among Black or Asian versus White people, and among people without versus with a previous event. The estimated whole-population increases in risk of arterial thromboses and VTEs 49 weeks after COVID-19 diagnosis were 0.5% and 0.25%, respectively, corresponding to 7200 and 3500 additional events, respectively, after 1.4 million COVID-19 diagnoses. Conclusions: High relative incidence of vascular events soon after COVID-19 diagnosis declines more rapidly for arterial thromboses than VTEs. However, incidence remains elevated up to 49 weeks after COVID-19 diagnosis. These results support policies to prevent severe COVID-19 by means of COVID-19 vaccines, early review after discharge, risk factor control, and use of secondary preventive agents in high-risk patients.

22 July 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JCJulia Carrasco-Zanini
Julia Carrasco-Zanini
MPMaik Pietzner
Maik Pietzner
JDJonathan Davitte
Jonathan Davitte
PSPraveen Surendran
Praveen Surendran
DCDamien C. Croteau-Chonka
Damien C. Croteau-Chonka
CLClaudia Langenberg
Claudia Langenberg
For many diseases there are delays in diagnosis due to a lack of objective biomarkers for disease onset. Here, in 41,931 individuals from the United Kingdom Biobank Pharma Proteomics Project, we integrated measurements of ~3,000 plasma proteins with clinical information to derive sparse prediction models for the 10-year incidence of 218 common and rare diseases (81–6,038 cases). We then compared prediction models developed using proteomic data with models developed using either basic clinical information alone or clinical information combined with data from 37 clinical assays. The predictive performance of sparse models including as few as 5 to 20 proteins was superior to the performance of models developed using basic clinical information for 67 pathologically diverse diseases (median delta C-index = 0.07; range = 0.02–0.31). Sparse protein models further outperformed models developed using basic information combined with clinical assay data for 52 diseases, including multiple myeloma, non-Hodgkin lymphoma, motor neuron disease, pulmonary fibrosis and dilated cardiomyopathy. For multiple myeloma, single-cell RNA sequencing from bone marrow in newly diagnosed patients showed that four of the five predictor proteins were expressed specifically in plasma cells, consistent with the strong predictive power of these proteins. External replication of sparse protein models in the EPIC-Norfolk study showed good generalizability for prediction of the six diseases tested. These findings show that sparse plasma protein signatures, including both disease-specific proteins and protein predictors shared across several diseases, offer clinically useful prediction of common and rare diseases.

19 January 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CDCaroline E. Dale
Caroline E. Dale
RTRohan Takhar
Rohan Takhar
RCRaymond Carragher
Raymond Carragher
MKMichail Katsoulis
Michail Katsoulis
FTFatemeh Torabi
Fatemeh Torabi
CCCVD-COVID-UK Consortium
CVD-COVID-UK Consortium
How the Coronavirus Disease 2019 (COVID-19) pandemic has affected prevention and management of cardiovascular disease (CVD) is not fully understood. In this study, we used medication data as a proxy for CVD management using routinely collected, de-identified, individual-level data comprising 1.32 billion records of community-dispensed CVD medications from England, Scotland and Wales between April 2018 and July 2021. Here we describe monthly counts of prevalent and incident medications dispensed, as well as percentage changes compared to the previous year, for several CVD-related indications, focusing on hypertension, hypercholesterolemia and diabetes. We observed a decline in the dispensing of antihypertensive medications between March 2020 and July 2021, with 491,306 fewer individuals initiating treatment than expected. This decline was predicted to result in 13,662 additional CVD events, including 2,281 cases of myocardial infarction and 3,474 cases of stroke, should individuals remain untreated over their lifecourse. Incident use of lipid-lowering medications decreased by 16,744 patients per month during the first half of 2021 as compared to 2019. By contrast, incident use of medications to treat type 2 diabetes mellitus, other than insulin, increased by approximately 623 patients per month for the same time period. In light of these results, methods to identify and treat individuals who have missed treatment for CVD risk factors and remain undiagnosed are urgently required to avoid large numbers of excess future CVD events, an indirect impact of the COVID-19 pandemic.

22 February 2024 in Scientific Data
Verified
Journal Article
Open access
PDF file
MPMarta Pineda-Moncusí
Marta Pineda-Moncusí
FAFreya Allery
Freya Allery
ADAntonella Delmestri
Antonella Delmestri
TBThomas Bolton
Thomas Bolton
JNJohn Nolan
John Nolan
OCon behalf of the CVD-COVID-UK/COVID-IMPACT Consortium
on behalf of the CVD-COVID-UK/COVID-IMPACT Consortium
Intersectional social determinants including ethnicity are vital in health research. We curated a population-wide data resource of self-identified ethnicity data from over 60 million individuals in England primary care, linking it to hospital records. We assessed ethnicity data in terms of completeness, consistency, and granularity and found one in ten individuals do not have ethnicity information recorded in primary care. By linking to hospital records, ethnicity data were completed for 94% of individuals. By reconciling SNOMED-CT concepts and census-level categories into a consistent hierarchy, we organised more than 250 ethnicity sub-groups including and beyond “White”, “Black”, “Asian”, “Mixed” and “Other, and found them to be distributed in proportions similar to the general population. This large observational dataset presents an algorithmic hierarchy to represent self-identified ethnicity data collected across heterogeneous healthcare settings. Accurate and easily accessible ethnicity data can lead to a better understanding of population diversity, which is important to address disparities and influence policy recommendations that can translate into better, fairer health for all.

1 November 2021 in Journal of the Royal Society of Medicine
Verified
Journal Article
Open access
PDF file
DGDeepti Gurdasani
Deepti Gurdasani
SBSamir Bhatt
Samir Bhatt
ACAnthony Costello
Anthony Costello
SDSpiros Denaxas
Spiros Denaxas
SFSeth Flaxman
Seth Flaxman
CPChristina Pagel
Christina Pagel
Objective: To offer a quantitative risk–benefit analysis of two doses of SARS-CoV-2 vaccination among adolescents in England. Setting: England. Design: Following the risk–benefit analysis methodology carried out by the US Centers for Disease Control, we calculated historical rates of hospital admission, Intensive Care Unit admission and death for ascertained SARS-CoV-2 cases in children aged 12–17 in England. We then used these rates alongside a range of estimates for incidence of long COVID, vaccine efficacy and vaccine-induced myocarditis, to estimate hospital and Intensive Care Unit admissions, deaths and cases of long COVID over a period of 16 weeks under assumptions of high and low case incidence. Participants: All 12–17 year olds with a record of confirmed SARS-CoV-2 infection in England between 1 July 2020 and 31 March 2021 using national linked electronic health records, accessed through the British Heart Foundation Data Science Centre. Main outcome measures: Hospitalisations, Intensive Care Unit admissions, deaths and cases of long COVID averted by vaccinating all 12–17 year olds in England over a 16-week period under different estimates of future case incidence. Results: At high future case incidence of 1000/100,000 population/week over 16 weeks, vaccination could avert 4430 hospital admissions and 36 deaths over 16 weeks. At the low incidence of 50/100,000/week, vaccination could avert 70 hospital admissions and two deaths over 16 weeks. The benefit of vaccination in terms of hospitalisations in adolescents outweighs risks unless case rates are sustainably very low (below 30/100,000 teenagers/week). Benefit of vaccination exists at any case rate for the outcomes of death and long COVID, since neither have been associated with vaccination to date. Conclusions: Given the current (as at 15 September 2021) high case rates (680/100,000 population/week in 10–19 year olds) in England, our findings support vaccination of adolescents against SARS-CoV2.

18 March 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
THTuankasfee Hama
Tuankasfee Hama
MAMohanad M Alsaleh
Mohanad M Alsaleh
FAFreya Allery
Freya Allery
JCJung Won Choi
Jung Won Choi
CTChristopher Tomlinson
Christopher Tomlinson
JTJohan H Thygesen
Johan H Thygesen
Background: The use of structured electronic health records in health care systems has grown rapidly. These systems collect huge amounts of patient information, including diagnosis codes representing temporal medical history. Sequential diagnostic information has proven valuable for predicting patient outcomes. However, the extent to which these types of data have been incorporated into deep learning (DL) models has not been examined. Objective: This systematic review aims to describe the use of sequential diagnostic data in DL models, specifically to understand how these data are integrated, whether sample size improves performance, and whether the identified models are generalizable. Methods: Relevant studies published up to May 15, 2023, were identified using 4 databases: PubMed, Embase, IEEE Xplore, and Web of Science. We included all studies using DL algorithms trained on sequential diagnosis codes to predict patient outcomes. We excluded review articles and non–peer-reviewed papers. We evaluated the following aspects in the included papers: DL techniques, characteristics of the dataset, prediction tasks, performance evaluation, generalizability, and explainability. We also assessed the risk of bias and applicability of the studies using the Prediction Model Study Risk of Bias Assessment Tool (PROBAST). We used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist to report our findings. Results: Of the 740 identified papers, 84 (11.4%) met the eligibility criteria. Publications in this area increased yearly. Recurrent neural networks (and their derivatives; 47/84, 56%) and transformers (22/84, 26%) were the most commonly used architectures in DL-based models. Most studies (45/84, 54%) presented their input features as sequences of visit embeddings. Medications (38/84, 45%) were the most common additional feature. Of the 128 predictive outcome tasks, the most frequent was next-visit diagnosis (n=30, 23%), followed by heart failure (n=18, 14%) and mortality (n=17, 13%). Only 7 (8%) of the 84 studies evaluated their models in terms of generalizability. A positive correlation was observed between training sample size and model performance (area under the receiver operating characteristic curve; P=.02). However, 59 (70%) of the 84 studies had a high risk of bias. Conclusions: The application of DL for advanced modeling of sequential medical codes has demonstrated remarkable promise in predicting patient outcomes. The main limitation of this study was the heterogeneity of methods and outcomes. However, our analysis found that using multiple types of features, integrating time intervals, and including larger sample sizes were generally related to an improved predictive performance. This review also highlights that very few studies (7/84, 8%) reported on challenges related to generalizability and less than half (38/84, 45%) of the studies reported on challenges related to explainability. Addressing these shortcomings will be instrumental in unlocking the full potential of DL for enhancing health care outcomes and patient care. Trial Registration: PROSPERO CRD42018112161; https://tinyurl.com/yc6h9rwu